Federal pharmacy law and regulated products
Federal pharmacy jurisprudence begins by identifying the legal activity, responsible actor, and applicable source. The FDA regulates drug approval, labeling, manufacturing quality, and other requirements under the Food, Drug, and Cosmetic Act. DEA administers controlled-substance registration and diversion controls. HRSA oversees the federal 340B program, while HHS administers HIPAA privacy and security requirements. These responsibilities overlap at a pharmacy but are not interchangeable. A valid DEA registration does not replace District professional licensure, and an NPI identifies a provider for standard transactions rather than establishing controlled-substance authority.
For controlled prescriptions, distinguish the schedule, the method of transmission, the patient's circumstances, and the particular exception invoked. Schedule II prescriptions cannot be refilled. Schedule III and IV refills have both an authorized-number ceiling and a six-month timing ceiling. Do not extend that ceiling indiscriminately to every Schedule V situation. Emergency oral Schedule II prescribing is a limited exception, with a quantity adequate for the emergency period, immediate documentation, verification when the practitioner is unfamiliar, and required follow-up. A universal emergency quantity such as an automatic seventy-two-hour supply is not what the federal emergency rule states.
Partial fills have different pathways. Insufficient stock under 21 CFR 1306.13(a) has a seventy-two-hour completion rule. A qualifying patient- or practitioner-requested partial fill under subsection (b) generally has a thirty-day deadline measured from the prescription date, with special emergency timing and state-law conditions. Long-term-care and terminal-illness provisions must be evaluated separately. Never choose a deadline merely because it appears elsewhere in the chapter.
Product regulation also involves distinctions. Misbranding concerns labeling and related violations; adulteration includes manufacturing or quality defects, and a product can meet more than one legal category. An ANDA establishes the applicable generic approval requirements, while therapeutic-equivalence evaluations do not by themselves authorize every local substitution. A REMS is a product-specific risk-management program, not a synonym for all patient education. Compounding standards distinguish nonsterile, sterile, and hazardous-drug activities; a USP chapter is not a substitute for reading the legal conditions that apply to the particular practice.
Finally, retain traceable records and verify current requirements. DEA inventory, purchasing, destruction, and theft reporting have different records and procedures. DSCSA product-tracing obligations must not be taught solely from obsolete transaction-history summaries. These questions provide independent foundations, not a complete current legal compliance manual or an official examination blueprint.